Komori
Sumitomo Seika Chemicals Company,Limited. (4008) · PolicyAdvanced

Policy of Reviewing the Rationale for Strategic Shareholdings Annually

First written in FY2020. 2 of 5 entries say "Restated". Latest entry: FY2026.

5entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2020 – FY2022AdvancedFY2023 – FY20262020: 120202021: 120212022: 120222023: 120232024: 020242025: 020252026: 12026
Same theme, other companies
Review of the Rationale for Holding Strategic ShareholdingsA theme 1259 companies write about · 1 as a headwind · 667 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1263 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「(Holdings with a decrease in the number of shares during the fiscal year) Shares other than unlisted shares 2 1,049」

    Following its review of cross-shareholdings, the Company sold 2 listed holdings, for total proceeds of ¥1,049 million.
  2. FY2023AdvancedAnnual report

    「Holdings with a decrease in the number of shares during the fiscal year: shares other than unlisted shares 4 735」

    Following its review of the rationale for cross-shareholdings, the Company sold 4 listed holdings, for total proceeds of ¥735 million. The disclosure states that the annual Board of Directors review policy led to actual selling activity.
  3. FY2022RestatedAnnual report

    「The Board of Directors reviews and verifies the rationale for each holding annually by qualitatively assessing the appropriateness of the purpose of the holding and quantitatively assessing whether the benefits and risks of holding the shares are commensurate with the Company's cost of capital. For shares judged to have little rationale for continued ownership, the Company considers selling them as appropriate, taking into account factors such as share-price trends.」

    The policy of annually verifying the rationale for cross-shareholdings from the perspectives of benefits, risks and cost of capital remains in place.
  4. FY2021RestatedAnnual report

    「The Board of Directors reviews and verifies the rationale for each holding annually by qualitatively assessing the appropriateness of the purpose of the holding and quantitatively assessing whether the benefits and risks of holding the shares are commensurate with the Company's cost of capital.」

    The policy of annually verifying the rationale for cross-shareholdings from the perspectives of benefits, risks and cost of capital remains in place.
  5. FY2020First statedAnnual report

    「The Board of Directors reviews and verifies the rationale for each holding annually by qualitatively assessing the appropriateness of the purpose of the holding and quantitatively assessing whether the benefits and risks of holding the shares are commensurate with the Company's cost of capital. For shares judged to have little rationale for continued ownership, the Company considers selling them as appropriate, taking into account factors such as share-price trends.」

    The Company has, for the first time, specifically stated a policy under which the Board of Directors annually verifies the purpose of cross-shareholdings, their benefits and risks, and their suitability relative to the cost of capital, and considers selling holdings with little rationale.
Moved together

"Expansion of consolidated performance with higher revenue and operating income" moved the same way as this thread, in the same document, in 2 of its 5 moves.

222222★123456
  1. ★This thread
  2. 1Expansion of consolidated performance with higher revenue and operating income2×
  3. 2Financial Base with a 52.2% Equity Ratio2×
  4. 3Payment of Year-End Dividends2×
  5. 4Initiatives to establish Medical and Lifestyle, Environment and Energy, and Electronics as new business domains2×
  6. 5Foreign exchange losses from sharp currency movements2×
  7. 6Continued investment in research and development2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Sumitomo Seika Chemicals Company,Limited. yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Policy of Reviewing the Rationale for Strategic Shareholdings Annually | Sumitomo Seika Chemicals Company,Limited. (4008) | Komori